Charles Theuer - Nov 2, 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc. (TCON)

Role: President and CEO, Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Stock symbol: TCON
Transactions as of: Nov 2, 2022
Transactions value $: $9,540
Form type: 4
Date filed: 11/3/2022, 06:00 AM
Previous filing: Oct 11, 2022
Next filing: Nov 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock	Purchase	$9.54K	+6K	+2.14%	$1.59	287K	Nov 2, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5897 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2	Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2022.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5897 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2022.